SCHEMBL22905422

SCHEMBL22905422

Cc1cc2c(o1)CCC/C2=N/O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.59
TSHR P16473 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
LMNA P02545 1/20 0.37
MAPK1 P28482 1/20 0.37
HPGD P15428 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA3 P07451 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36
CA5A P35218 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA13 Q8N1Q1 1/20 0.36
CA14 Q9ULX7 1/20 0.36
CA5B Q9Y2D0 1/20 0.36
USP2 O75604 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22905512 0.81 POLB (0.58) POLBTSHRSMN1; SMN2NPC1LMNA
SCHEMBL22606339 0.75 POLB (0.41) POLBTSHRSMN1; SMN2NPC1LMNA
SCHEMBL22905633 0.72 TDP1 (0.58) POLBTSHRSMN1; SMN2LMNAHPGD
SCHEMBL22905581 0.72 POLB (0.60) POLBTSHRSMN1; SMN2NPC1LMNA
SCHEMBL10426958 0.72 TDP1 (0.53) POLBTSHRSMN1; SMN2NPC1MAPK1
SCHEMBL3135172 0.68 TDP1 (0.53) POLBTSHRSMN1; SMN2NPC1MAPK1
SCHEMBL22905411 0.68 HPGD (0.33) HPGDCA12CA1CA3CA4
SCHEMBL22905485 0.68 TDP1 (0.38) CA12CA1CA3CA4CA6
SCHEMBL2588817 0.67 MAPT (0.52) POLBTSHRLMNAMAPK1HPGD
SCHEMBL2588819 0.67 MAPT (0.52) POLBTSHRLMNAMAPK1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021009566-A1 N-((1,2,3,5,6,7-HEXAHYDRO-S-INDACEN-4-YL)CARBAMOYL)-4,5,6,7-TETRAHYDROBENZOFURAN -2-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NLPR3 MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS (MS) ZOMAGEN BIOSCIENCES LTD (US) 2021-01-21 WO disclosed